A complete surgical resection is the most important objective of cancer surgery. Yet the methods currently used to identify malignant tissue are limited – skilled surgeons often rely on a suboptimal patchwork of pre-operative imaging and real time visual and tactile cues.
To date, there has been no reliable way for surgeons to assess the location and full extent of cancerous tissue while operating.
The compound is administered to the patient via IV infusion anytime between 1 to 24 hours prior to the procedure, as best fits the procedure workflow and patient needs.
With the help of a near-infrared camera, the surgeon is able to see malignant tissue during the operation. This illumination may enable various benefits, including
Localization of primary lesion
Assessment of surgical margin
Identification of synchronous lesions
Identification of additional cancerous lesions
We’re developing technology where it’s needed most.
Lung, ovarian, prostate, and colorectal cancers alone make up nearly 72% of inpatient oncology procedures in the US1. On Target is the first to bring intraoperative targeted fluorescent markers to lung and ovarian cancers, with more indications in our pipeline. The potential of this technology has us committed to expanding our portfolio and increasing the number of complete surgical resections for cancer patients.
1 Orosco, Ryan, et al. Positive Surgical Margins in the 10 Most Common Solid Cancers. Nature. 2018; 8:5686. doi:10.1038/s41598-018-23403-5
Clinical trials are underway in more than a dozen centers to evaluate On Target Laboratories’s portfolio.
This study is to confirm the efficacy of OTL38 in combination with near-infrared fluorescence imaging to detect additional ovarian cancer lesions not detected by palpation and visualization under normal light during surgeryLearn More
This study aims to assess the efficacy, safety, and tolerability of OTL38 and near-infrared fluorescence imaging at identifying pulmonary nodules within the operating theaterLearn More
This study is to assess the safety, tolerability and pharmacokinetics of OTL78, a PSMA-targeted fluorescent marker, for the intraoperative imaging of prostate cancerLearn more